Syngene Reports FY26 Revenue Up 3% as Margins Slip to 25%

Syngene FY26 Financial Highlights

• Revenue: Rs 3,739 cr (+3% YoY) for the year; Rs 1,037 cr (+2% YoY) in Q4.
• Operating EBITDA margin: 25% FY26 (down from 29% FY25).
• PAT (before exceptional items): Rs 380 cr (-20% YoY).
• Cash generation: Rs 521 cr net cash from operations.
• Dividend: Final dividend of Rs 1.25 per share recommended.

Key Management & Board Changes

• Kiran Mazumdar‑Shaw elevated to Executive Chairperson (5‑year term, effective 1 Apr 2026).
• Siddharth Mittal appointed MD & CEO (effective 1 Jul 2026), succeeding Peter Bains.
• New independent directors Vijaya Chandru and Arun Chandavarkar; re‑appointment of Vinita Bali.
• Maninder Kapoor Puri joins as Chief Human Resources Officer; Abhijit Zutshi as Chief Commercial Officer – both from Biocon.

Strategic Initiatives

• ADC Capability Expansion: Launch of an ADC discovery laboratory and GMP bioconjugation suite, creating an end‑to‑end platform for high‑potency compounds.
• Quality & Compliance: Completed 14 client/regulatory audits (85 YTD) and obtained GCP‑NABL accreditation.
• ESG Recognition: Ranked in the top‑10 life‑sciences companies in the S&P Global Sustainability Yearbook 2026 and named an ‘Industry Mover’ for CSA score improvement.
• Digital & AI Investments: Ongoing projects to enhance speed, productivity, and value creation for clients.

Financial Position (Balance Sheet Highlights)

• Total assets: Rs 70,547 mn (up from Rs 67,959 mn).
• Cash & equivalents: Rs 2,286 mn (down from Rs 3,671 mn) but still sizable.
• Borrowings: Reduced dramatically to Rs 94 mn from Rs 1,196 mn, indicating deleveraging.
• Current liabilities: Increased to Rs 15,523 mn (from Rs 13,964 mn) driven by higher trade payables and provisions.

Risks & Opportunities

• Risks: Margin compression, rising staff and termination costs, exceptional items from new labour codes, concentration in a few large biologics clients, integration of new manufacturing capacity.
• Opportunities: Growing demand for ADCs and other novel modalities, AI‑driven service enhancements, strong ESG credentials attracting responsible investors, leadership with proven biotech experience.

Forward‑Looking Statements

Management expects FY26 performance to be in line with revised guidance, citing the impact of a single large‑molecule biologics client and the ramp‑up of the new biologics facility. The focus will remain on expanding high‑growth service lines, strengthening digital capabilities, and delivering shareholder value through dividends and strategic investments.

The investor call is scheduled for 30 Apr 2026 at 2 pm IST (dial‑in details in the release).